With 17.28 million shares changed hands, the volume of the stock remained heavier than its average volume of 4.27 million shares. During the session, the Specialty Chemicals company that operates in wider Basic Materials sector, reached to the highest price of $0.0488 whereas the lowest price it dropped to was $0.0425. The 52-week range on CRKN shows that it touched its highest point at $14.16 and its lowest point at $0.04 during that stretch. It currently has a 1-year price target of $90.00. Beta for the stock currently stands at 1.03.
Price Performance and Earnings:
Stock performance is one of the indicators that investors use to determine whether they will profit from a stock. The price performance of CRKN was down-trending over the past week, with a drop of -6.21%, but this was down by -14.91% over a month. Three-month performance dropped to -58.44% while six-month performance fell -82.33%. The stock lost -99.29% in the past year, while it has lost -68.27% so far this year.
Float and Shares Shorts:
At present, 51.70 million CRKN shares are outstanding with a float of 51.15 million shares on hand for trading. On 2024-04-15, short shares totaled 1.59 million, which was 307.0 higher than short shares on 1710460800. In addition to Mr. Douglas B. Croxall as the firm’s Chairman & CEO, Mr. Timothy Koch serves as its Co-Founder & CTO.
Institutional Ownership:
Through their ownership of 0.01286 of CRKN’s outstanding shares, institutional investors have minority control over the company.
An Overview of Recent Financials:
Understanding a company as a customer does not mean you will understand it as an investor. The wise investor uses quantitative research to analyze metrics such as revenue, net income, and earnings. In its fiscal quarter reported on 2023-12-31, CRKN reported revenue of $94000.0 and operating income of -$6215000.0. Over the past year, revenue came in at $0.00 while operating income stood at -$19.01M. It generated -$9306000.0 net income for the quarter, which came to -$35.63M over the last twelve months. The EBITDA in the recently reported quarter was -$6244000.0 and diluted EPS was $nan. EBITDA for the full year was -$18.85M.
Analysts Ratings:
Reading analyst opinions is an effective way to decide where to invest, and there are several opinions available for CRKN since 0 analysts follow the stock currently. In the same way, a target price assigned to a stock can also reveal much about its potential.
